María-Victoria Mateos, Nizar Bahlis, Aurore Perrot, Ajay Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gaston Caeiro, Alain Kentos, Vania Hungria, Donna Reece, Ting Niu, Anne Mylin, Charlotte Hansen, Raphael Teipel, Britta Besemer, Meletios Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kim, Chang-Ki Min, Paulus Geerts, Elena Van Leeuwen-Segarceanu, Agata Tyczyńska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodriguez-Otero, Joaquín Martínez-López, Hamza Hashmi, Robin Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Debbie Briseno-Toomey, Lisa O'Rourke, Maria Rubin, Diego Vieyra, Lijuan Kang, Luciano Costa. "Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3." Blood, 2025. doi:10.1182/blood-2025-lba-6